|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McDermott AM, Miller N, Wall D, Martyn LM,
Ball G, Sweeney KJ and Kerin MJ: Identification and validation of
oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS
One. 9:e870322014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Notas G, Pelekanou V, Kampa M, Alexakis K,
Sfakianakis S, Laliotis A, Askoxilakis J, Tsentelierou E, Tzardi M,
Tsapis A and Castanas E: Tamoxifen induces a pluripotency signature
in breast cancer cells and human tumors. Mol Oncol. 9:1744–1759.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahmed S, Sami A and Xiang J: HER2-directed
therapy: Current treatment options for HER2-positive breast cancer.
Breast Cancer. 22:101–116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karlsson E, Veenstra C, Emin S, Dutta C,
Pérez-Tenorio G, Nordenskjöld B, Fornander T and Stål O: Loss of
protein tyrosine phosphatase, non-receptor type 2 is associated
with activation of AKT and tamoxifen resistance in breast cancer.
Breast Cancer Res Treat. 153:31–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boulbes DR, Chauhan GB, Jin Q,
Bartholomeusz C and Esteva FJ: CD44 expression contributes to
trastuzumab resistance in HER2-positive breast cancer cells. Breast
Cancer Res Treat. 151:501–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Reilly EA, Gubbins L, Sharma S, Tully R,
Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell
M and McCann A: The fate of chemoresistance in triple negative
breast cancer (TNBC). BBA Clin. 3:257–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Venkatesh T, Suresh PS and Tsutsumi R:
Non-coding RNAs: Functions and applications in endocrine-related
cancer. Mol Cell Endocrinol. 416:88–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calore F, Lovat F and Garofalo M:
Non-coding RNAs and cancer. Int J Mol Sci. 14:17085–17110. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanwar JR, Mahidhara G and Kanwar RK:
MicroRNA in human cancer and chronic inflammatory diseases. Front
Biosci (Schol Ed). 2:1113–1126. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lowery AJ, Miller N, Devaney A, McNeill
RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G and
Kerin MJ: MicroRNA signatures predict oestrogen receptor,
progesterone receptor and HER2/neu receptor status in breast
cancer. Breast Cancer Res. 11:R272009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui S, Liao X, Ye C, Yin X, Liu M, Hong Y,
Yu M, Liu Y, Liang H, Zhang CY and Chen X: ING5 suppresses breast
cancer progression and is regulated by miR-24. Mol Cancer.
16:892017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi Y, Luo X, Li P, Tan J, Wang X, Xiang T
and Ren G: miR-7-5p suppresses cell proliferation and induces
apoptosis of breast cancer cells mainly by targeting REGγ. Cancer
Lett. 358:27–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raychaudhuri M, Bronger H, Buchner T,
Kiechle M, Weichert W and Avril S: MicroRNAs miR-7 and miR-340
predict response to neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res Treat. 162:511–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsai HP, Huang SF, Li CF, Chien HT and
Chen SC: Differential microRNA expression in breast cancer with
different onset age. PLoS One. 13:e01911952018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Finlin BS, Gau CL, Murphy GA, Shao H,
Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, et al:
RERG is a novel ras-related, estrogen-regulated and
growth-inhibitory gene in breast cancer. J Biol Chem.
276:42259–42267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS,
Gao HW and Yu CP: MicroRNA-382-5p aggravates breast cancer
progression by regulating the RERG/Ras/ERK signaling axis.
Oncotarget. 8:22443–22459. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kasinski AL and Slack FJ: miRNA-34
prevents cancer initiation and progression in a therapeutically
resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Cancer Res. 72:5576–5587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tung SL, Huang WC, Hsu FC, Yang ZP, Jang
TH, Chang JW, Chuang CM, Lai CR and Wang LH: miRNA-34c-5p inhibits
amphiregulin-induced ovarian cancer stemness and drug resistance
via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis.
6:e3262017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kong W, He L, Richards EJ, Challa S, Xu
CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and
Cheng JQ: Upregulation of miRNA-155 promotes tumour angiogenesis by
targeting VHL and is associated with poor prognosis and
triple-negative breast cancer. Oncogene. 33:679–689. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allen KE and Weiss GJ: Resistance may not
be futile: microRNA biomarkers for chemoresistance and potential
therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu L, Xue F, Xu X, Xu J, Hu S, Liu S, Cui
Y and Gao C: MicroRNA-198 inhibition of HGF/c-MET signaling pathway
overcomes resistance to radiotherapy and induces apoptosis in human
non-small-cell lung cancer. J Cell Biochem. 119:7873–7886. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Blenkiron C, Goldstein LD, Thorne NP,
Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE,
Green AR, Ellis IO, et al: MicroRNA expression profiling of human
breast cancer identifies new markers of tumor subtype. Genome Biol.
8:R2142007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Volinia S, Galasso M, Sana ME, Wise TF,
Palatini J, Huebner K and Croce CM: Breast cancer signatures for
invasiveness and prognosis defined by deep sequencing of microRNA.
Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mirzoeva OK, Das D, Heiser LM,
Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM,
Guan Y, et al: Basal subtype and MAPK/ERK kinase
(MEK)-phosphoinositide 3-kinase feedback signaling determine
susceptibility of breast cancer cells to MEK inhibition. Cancer
Res. 69:565–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao W, Ma N, Wang S, Mo Y, Zhang Z, Huang
G, Midorikawa K, Hiraku Y, Oikawa S, Murata M and Takeuchi K: RERG
suppresses cell proliferation, migration and angiogenesis through
ERK/NF-κB signaling pathway in nasopharyngeal carcinoma. J Exp Clin
Cancer Res. 36:942017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang AG, Fang W, Han YH, Cho SM, Choi JY,
Lee KH, Kim WH, Kim JM, Park MG, Yu DY, et al: Expression of the
RERG gene is gender-dependent in hepatocellular carcinoma and
regulated by histone deacetyltransferases. J Korean Med Sci.
21:891–896. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Y, Ren S, Yuan F, Zhang K, Fan Y,
Zheng S, Gao Z, Zhao J, Mu T, Zhao S, et al: miR-135 promotes
proliferation and stemness of oesophageal squamous cell carcinoma
by targeting RERG. Artif Cells Nanomed Biotechnol. 46
(Suppl):1210–1219. 2018. View Article : Google Scholar : PubMed/NCBI
|
